Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Assessment of drug half-life
Timeframe: Through study completion, an average of 4 weeks
Assessment of immune globulin G serum concentration after intravenous immune globulin G administration
Timeframe: Just before drug administration, immediately after drug administration, approximately days 7 and 14 post drug administration
Assessment of immune globulin G serum concentration after subcutaneous immune globulin G administration
Timeframe: Just before drug administration, immediately after drug administration, approximately days 2, 4 and 7 post drug administration